HNSBF Stock Chart & Stats
$3.70
$0.00(0.00%)
At close: 4:00 PM EDT
$3.70
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.90 - $4.58
Previous CloseN/A
Volume8.00K
Average Volume (3M)200.00
Market Cap
$407.42M
Enterprise Value$4.01B
Total Cash (Recent Filing)$552.81M
Total Debt (Recent Filing)$1.03B
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Nov 11, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.86
Shares Outstanding101,763,220
10 Day Avg. Volume0
30 Day Avg. Volume200
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market Cap9.85
Enterprise Value/Revenue21.17
Enterprise Value/Gross Profit36.94
Enterprise Value/Ebitda-7.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$47.61M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership And LiquidityThe SERB transaction provides substantial funding ahead of potential U.S. approval and extends operating runway. This strengthens Hansa’s ability to finance commercialization, regulatory work and pipeline development while reducing immediate dependence on additional external capital.
Strong Clinical EvidenceRobust confirmatory data support imlifidase’s clinical value in highly sensitized transplant patients and strengthen the case for continued adoption. Positive PAES results also support conversion to full European approval, expanding the product’s regulatory durability.
U.S. Commercial ExpansionA defined U.S. regulatory and launch timetable creates a credible path to geographic expansion beyond the current European business. Preparing leading transplant centers and pursuing reimbursement mechanisms could support broader adoption if approval is secured.
Bears Say
Persistent Losses And Cash BurnDeep operating losses and consistently negative cash generation show that the business has not yet reached a self-funding scale. Continued investment in commercialization and development may require substantial financing unless revenue growth and operating leverage improve materially.
Negative Equity And High DebtA negative equity position combined with sizeable debt weakens financial resilience and restricts capital-allocation flexibility. If losses persist, Hansa may face greater refinancing pressure and fewer options to fund expansion without shareholder or creditor support.
Clinical And Adoption HurdlesThe higher observed antibody-mediated rejection rate remains a clinically important consideration even though management reported it was manageable and caused no graft losses. Addressing this issue and center-level readiness may slow physician adoption and market expansion.
Hansa Biopharma AB News
HNSBF FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was $2.90 and its highest was $4.58 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is $407.42M.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 11, 2026 which is in 11 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -$0.261 earnings per share for the quarter, missing the consensus estimate of -$0.034 by -$0.226.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Overvalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is -0.14.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -$0.261 in its last earnings report, missing expectations of -$0.034. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in HNSBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Cantargia AB
―
Ownership Overview
―
Insiders
3.13% Mutual Funds
― Other Institutional Investors
96.65% Public Companies and
Individual Investors